Steven Fishbane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Steven Fishbane has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Hitesh H. Shah
Division of Kidney Diseases and Hypertension, Northwell Health, Zucker School of Medicine, Great Neck, NY
8 shared publicationsBruce Spinowitz
Division of Nephrology, Department of Medicine, New York Presbyterian Queens, Flushing, New York
6 shared publicationsNicolas Guzman
BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
6 shared publicationsAnjay Rastogi
Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
5 shared publicationsAyman Al-Shurbaji
BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
5 shared publicationsCandice Halinski
5 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Wolters Kluwer Health in Kidney360
Effects of Sodium Zirconium Cyclosilicate on Volume Status in Maintenance Hemodialysis
Background: The Effect of Sodium Zirconium Cyclosilicate on Arrythmia-Related Cardiovascular Outcomes in Participants on Chronic Hemodialysis with Recurrent Hyperkalemia (DIALIZE-Outcomes) trial evaluated the effect of sodium zirconium cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes among patients receiving maintenance hemodialysis. The study was terminated early because of a low event rate and high treatment discontinuation. As SZC exchanges sodium for potassium, volume expansion from increased sodium absorption is a potential adverse effect. This post hoc analysis evaluated the effects of SZC versus placebo on volume status. Methods: Adults receiving maintenance hemodialysis with predialysis hyperkalemia (serum potassium ≥5.5 mmol/L) were randomized 1:1 to SZC (starting dose 5 g once daily on non-dialysis days, titrated as needed; N =1349) or placebo ( N =1341). Indicators of volume status included: adverse events (AEs) related to volume status, antihypertensive medication use, change in predialysis blood pressure, and change in interdialytic weight gain (IDWG). Results: For the 2690 randomized participants, 62% were male, mean (SD) age was 56.1 (13.4) years, predialysis weight was 75.3 (19.8) kg, and dialysis vintage was 5.9 (5.3) years. In the SZC and placebo groups, there were similar proportions of participants with AEs of edema (5% versus 5%), heart failure (5% versus 5%), and hypertension (9% versus 8%). Mean (SD) changes from baseline to end of follow-up were similar between SZC and placebo for predialysis systolic (-2.1 [24.3] versus -2.2 [22.2] mm Hg) and diastolic (-0.9 [15.0] versus -0.8 [14.2] mm Hg) blood pressure, and IDWG (+0.2 [2.6] versus +0.1 [2.4] kg). The number of antihypertensive medications used was similar between SZC and placebo at baseline (85% versus 83%) and during follow-up (88% versus 86%). Conclusions: In this post hoc analysis of a large trial of patients with hyperkalemia receiving hemodialysis, there was no clinical evidence of volume changes with SZC. This supports the use of SZC as hyperkalemia treatment among patients receiving hemodialysis—a population at high risk for hypervolemia.
- 6 August 2026
- Published by Wolters Kluwer Health in Kidney360
Open AccessEffects of Sodium Zirconium Cyclosilicate on Volume Status in Maintenance Hemodialysis
Background: The Effect of Sodium Zirconium Cyclosilicate on Arrythmia-Related Cardiovascular Outcomes in Participants on Chronic Hemodialysis with Recurrent Hyperkalemia (DIALIZE-Outcomes) trial evaluated the effect of sodium zirconium cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes among patients receiving maintenance hemodialysis. The study was terminated early because of a low event rate and high treatment discontinuation. As SZC exchanges sodium for potassium, volume expansion from increased sodium absorption is a potential adverse effect. This post hoc analysis evaluated the effects of SZC versus placebo on volume status. Methods: Adults receiving maintenance hemodialysis with predialysis hyperkalemia (serum potassium ≥5.5 mmol/L) were randomized 1:1 to SZC (starting dose 5 g once daily on non-dialysis days, titrated as needed; N =1349) or placebo ( N =1341). Indicators of volume status included: adverse events (AEs) related to volume status, antihypertensive medication use, change in predialysis blood pressure, and change in interdialytic weight gain (IDWG). Results: For the 2690 randomized participants, 62% were male, mean (SD) age was 56.1 (13.4) years, predialysis weight was 75.3 (19.8) kg, and dialysis vintage was 5.9 (5.3) years. In the SZC and placebo groups, there were similar proportions of participants with AEs of edema (5% versus 5%), heart failure (5% versus 5%), and hypertension (9% versus 8%). Mean (SD) changes from baseline to end of follow-up were similar between SZC and placebo for predialysis systolic (-2.1 [24.3] versus -2.2 [22.2] mm Hg) and diastolic (-0.9 [15.0] versus -0.8 [14.2] mm Hg) blood pressure, and IDWG (+0.2 [2.6] versus +0.1 [2.4] kg). The number of antihypertensive medications used was similar between SZC and placebo at baseline (85% versus 83%) and during follow-up (88% versus 86%). Conclusions: In this post hoc analysis of a large trial of patients with hyperkalemia receiving hemodialysis, there was no clinical evidence of volume changes with SZC. This supports the use of SZC as hyperkalemia treatment among patients receiving hemodialysis—a population at high risk for hypervolemia.
- Open Access
- 24 December 2025
- Published by Elsevier in Kidney Medicine
- Vol. 8 (3) , 101231
Composite Primary Outcomes in Nephrology Clinical Trials
- 24 December 2025
- Published by Elsevier in Kidney Medicine
- Vol. 8 (3) , 101231
Open AccessComposite Primary Outcomes in Nephrology Clinical Trials
- Open Access
- 17 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1689698
Commentary: Efficacy and safety of HSK21542 for pruritus management in hemodialysis patients: a multicenter, randomized, double-blind, placebo-controlled trial
Statistical difference. In summary, the "superior efficacy" claim is may be misleading. In addition, the claim of superior safety for HSK21542 is also unsubstantiated. The safety relative to placebo was comparable: the incidence of treatment-emergent adverse events in the 0.3 μg/kg group (76.7%) was similar to placebo (73.3%). Thus, asserting an overall superior safety is incorrect. The 0.3 μg/kg HSK21542 appears to have a safety/tolerability profile similar to placebo, which is reassuring, but not "superior".High-dose (HSK21542 0.6 μg/kg) results: The findings for the higher 0.6 μg/kg dose which showed less itch relief vs placebo is under-addressed. The group difference was +1.03 points vs placebo, with a 95% CI of +0.01 to +2.07. Notably, this CI excludes zero, which implies a statistically significant worse result of the high dose vs placebo. The authors do not explicitly acknowledge this but simply describe the 0.6 μg/kg effect as "less pronounced" than that of 0.3 μg/kg and "although various efficacy endpoints in the 0.6 μg/kg dose group showed improvement from baseline, no significant dose-response relationship was observed compared to the 0.3 μg/kg dose group". These statements appear to understate the findings, as the data show a less favorable effect compared with placebo. These are understatements considering the data showed a worse effect compared to placebo. This is a relevant finding (possible U-shaped dose-response) that would be important to explore. I also note an omission in Table 2: the 5-D Itch score value is blank for the LS mean difference vs placebo for the 0.6 μg/kg group, with only the CI provided, which may be a formatting error. In summary, the significant worse lower itch improvement at 0.6 μg/kg vs placebo is an important result that warrants emphasis. In review BUSINESS USE Cross-Trial comparisons: In the discussion section, the outcomes of this Phase II trial are compared with difelikefalin trials for CKD-aP. They The authors report, that 62.1% of patients in the HSK21542 0.3 μg/kg group achieved ≥3-point WI-NRS improvement at 12 weeks, versus 49.1% and 53.4% in the Phase 3 KALM-1 and KALM-2 studies of difelikefalin, respectively. While these figures were correctly cited (2,4), cross-trial comparisons are potentially misleading. The patient population and study conditions differed and no matching or statistical comparison was performed. Contextualization is crucial important asand as directly comparing the responder percentages in separate trials without adjustment can may be misleading. The authors also draw parallels to the dose-response findings of difelikefalin's Phase II trial. They state that the lack of a dose-response (0.6 vs 0.3) in HSK21542 "mirrors the findings from the phase II study of difelikefalin, where the 0.5 μg/kg dose group exhibited better efficacy than the 1 μg/kg dose group". This comparison is may be imprecise because asthere was no statistical difference was observed between these groups, and the difelikefalin phase II trial showed a significant benefit or a trend towards a benefit of the drug vs placebo at all doses tested (0.5 μg/kg being optimal)(3). Given that the HSK21542 0.6 μg/kg dose group showed a statistically significant diminshed effect compared to placebo, drawing an analogy to difelikefalin may be misleading.Thus, considering the lack of efficacy for all HSK21542 dose groups, the analogy to difelikefalin seems misleading.Discussion: I urge recommend caution in interpreting the results of Pan et al.'s 2025 manuscript. The data do not demonstrate a significant benefit of HSK21542 0.3 μg/kg over placebo. I recommend that the authors and researchers ensure that statements in the abstract, discussion, and conclusion are fully supported by the results presented. Inadvertent mistakes, such as the missing number or minus symbol should may be corrected to avoid confusion. Comparing results to other studies without direct comparative data should be avoidedmade with caution. Accurate reporting of results with substantiated claims, will ultimately benefit the scientific community and patients by setting the stage for credible and reproducible findings in future trials. In summary, HSK21542 could be an interesting therapeutic candidate for CKD-aP, but the evidence from this Phase II study is not sufficient to prove superior efficacy and safety. We look forward to further studies that address these topics and clarify the role of HSK21542 in managing CKD-aP.In summary, authors must use care in the reporting of results. The repeated miststatements asserting efficacy in this study, when the results do not demonstrate significant efficacy vs. placebo, can be misleading for readers.
- 17 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1689698
Open AccessCommentary: Efficacy and safety of HSK21542 for pruritus management in hemodialysis patients: a multicenter, randomized, double-blind, placebo-controlled trial
Statistical difference. In summary, the "superior efficacy" claim is may be misleading. In addition, the claim of superior safety for HSK21542 is also unsubstantiated. The safety relative to placebo was comparable: the incidence of treatment-emergent adverse events in the 0.3 μg/kg group (76.7%) was similar to placebo (73.3%). Thus, asserting an overall superior safety is incorrect. The 0.3 μg/kg HSK21542 appears to have a safety/tolerability profile similar to placebo, which is reassuring, but not "superior".High-dose (HSK21542 0.6 μg/kg) results: The findings for the higher 0.6 μg/kg dose which showed less itch relief vs placebo is under-addressed. The group difference was +1.03 points vs placebo, with a 95% CI of +0.01 to +2.07. Notably, this CI excludes zero, which implies a statistically significant worse result of the high dose vs placebo. The authors do not explicitly acknowledge this but simply describe the 0.6 μg/kg effect as "less pronounced" than that of 0.3 μg/kg and "although various efficacy endpoints in the 0.6 μg/kg dose group showed improvement from baseline, no significant dose-response relationship was observed compared to the 0.3 μg/kg dose group". These statements appear to understate the findings, as the data show a less favorable effect compared with placebo. These are understatements considering the data showed a worse effect compared to placebo. This is a relevant finding (possible U-shaped dose-response) that would be important to explore. I also note an omission in Table 2: the 5-D Itch score value is blank for the LS mean difference vs placebo for the 0.6 μg/kg group, with only the CI provided, which may be a formatting error. In summary, the significant worse lower itch improvement at 0.6 μg/kg vs placebo is an important result that warrants emphasis. In review BUSINESS USE Cross-Trial comparisons: In the discussion section, the outcomes of this Phase II trial are compared with difelikefalin trials for CKD-aP. They The authors report, that 62.1% of patients in the HSK21542 0.3 μg/kg group achieved ≥3-point WI-NRS improvement at 12 weeks, versus 49.1% and 53.4% in the Phase 3 KALM-1 and KALM-2 studies of difelikefalin, respectively. While these figures were correctly cited (2,4), cross-trial comparisons are potentially misleading. The patient population and study conditions differed and no matching or statistical comparison was performed. Contextualization is crucial important asand as directly comparing the responder percentages in separate trials without adjustment can may be misleading. The authors also draw parallels to the dose-response findings of difelikefalin's Phase II trial. They state that the lack of a dose-response (0.6 vs 0.3) in HSK21542 "mirrors the findings from the phase II study of difelikefalin, where the 0.5 μg/kg dose group exhibited better efficacy than the 1 μg/kg dose group". This comparison is may be imprecise because asthere was no statistical difference was observed between these groups, and the difelikefalin phase II trial showed a significant benefit or a trend towards a benefit of the drug vs placebo at all doses tested (0.5 μg/kg being optimal)(3). Given that the HSK21542 0.6 μg/kg dose group showed a statistically significant diminshed effect compared to placebo, drawing an analogy to difelikefalin may be misleading.Thus, considering the lack of efficacy for all HSK21542 dose groups, the analogy to difelikefalin seems misleading.Discussion: I urge recommend caution in interpreting the results of Pan et al.'s 2025 manuscript. The data do not demonstrate a significant benefit of HSK21542 0.3 μg/kg over placebo. I recommend that the authors and researchers ensure that statements in the abstract, discussion, and conclusion are fully supported by the results presented. Inadvertent mistakes, such as the missing number or minus symbol should may be corrected to avoid confusion. Comparing results to other studies without direct comparative data should be avoidedmade with caution. Accurate reporting of results with substantiated claims, will ultimately benefit the scientific community and patients by setting the stage for credible and reproducible findings in future trials. In summary, HSK21542 could be an interesting therapeutic candidate for CKD-aP, but the evidence from this Phase II study is not sufficient to prove superior efficacy and safety. We look forward to further studies that address these topics and clarify the role of HSK21542 in managing CKD-aP.In summary, authors must use care in the reporting of results. The repeated miststatements asserting efficacy in this study, when the results do not demonstrate significant efficacy vs. placebo, can be misleading for readers.
- Open Access
- 4 July 2025
- Published by Elsevier in Kidney International
The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis
- 4 July 2025
- Published by Elsevier in Kidney International
Open AccessThe randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis
- 15 October 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (12) , 1656-1658
Challenges and Opportunities in Advanced Chronic Kidney Disease
An abstract is unavailable. This article is available as a PDF only.
- 15 October 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (12) , 1656-1658
Challenges and Opportunities in Advanced Chronic Kidney Disease
An abstract is unavailable. This article is available as a PDF only.
- 13 August 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (9) , 1084-1085
Automated Dialysis Anemia Management
- 13 August 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (9) , 1084-1085
Automated Dialysis Anemia Management
- Open Access
- 22 July 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (9) , 1270-1280
Pruritus Severity and Serum Phosphate in CKD: A Post Hoc Analysis of Difelikefalin Studies
Key Points: No correlation was observed between pruritus severity and serum phosphate or response to placebo or difelikefalin in patients with CKD-associated pruritus undergoing hemodialysis. Difelikefalin improved itch versus placebo irrespective of baseline serum phosphate. Background: CKD-associated pruritus (CKD-aP) has historically been associated with elevated serum phosphate (sP). Difelikefalin is a novel antipruritic agent approved for the treatment of moderate-to-severe CKD-aP in adults undergoing hemodialysis. This post hoc analysis used data from phase 3 difelikefalin studies (KALM-1, KALM-2, and open-label Study 3105) to assess the role of sP in the pathogenesis of CKD-aP and whether difelikefalin ameliorates CKD-aP in patients with and without elevated sP. Methods: Patients with moderate-to-severe CKD-aP undergoing hemodialysis with baseline sP data were included in the analysis (KALM-1 and KALM-2, n=845; Study 3105, n=220). Assessments included correlation between 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS) score and sP. Results: In KALM-1 and KALM-2, baseline characteristics in the overall population were similar between patients with sP ≤5.5 and >5.5 mg/dl; no significant correlation was observed between WI-NRS and sP at baseline or in week 12. In patients receiving placebo, no correlation was observed between WI-NRS and sP at baseline or between their change from baseline to week 12 (all P < 0.05). Clinically meaningful (≥3-point) reductions from baseline to week 12 in WI-NRS scores were reported by more patients receiving placebo with baseline sP ≤5.5 mg/dl than >5.5 mg/dl (least squares mean 37.2% versus 27.4%; odds ratio [95% confidence interval], 0.63 [0.41 to 0.97]; P = 0.04). A greater proportion of patients treated with difelikefalin achieved a ≥3-point WI-NRS reduction from baseline to week 12 versus placebo and was similar between sP ≤5.5 and >5.5 mg/dl subgroups (least squares means 51.1% versus 57.6% [P = 0.20]). No significant relationships between sP and WI-NRS in patients receiving difelikefalin were identified in Study 3105 at any time point. Conclusions: No correlation was observed between pruritus severity and sP or response to placebo or difelikefalin in patients with CKD-aP undergoing hemodialysis. Difelikefalin improved itch versus placebo irrespective of baseline sP.
- 22 July 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (9) , 1270-1280
Open AccessPruritus Severity and Serum Phosphate in CKD: A Post Hoc Analysis of Difelikefalin Studies
Key Points: No correlation was observed between pruritus severity and serum phosphate or response to placebo or difelikefalin in patients with CKD-associated pruritus undergoing hemodialysis. Difelikefalin improved itch versus placebo irrespective of baseline serum phosphate. Background: CKD-associated pruritus (CKD-aP) has historically been associated with elevated serum phosphate (sP). Difelikefalin is a novel antipruritic agent approved for the treatment of moderate-to-severe CKD-aP in adults undergoing hemodialysis. This post hoc analysis used data from phase 3 difelikefalin studies (KALM-1, KALM-2, and open-label Study 3105) to assess the role of sP in the pathogenesis of CKD-aP and whether difelikefalin ameliorates CKD-aP in patients with and without elevated sP. Methods: Patients with moderate-to-severe CKD-aP undergoing hemodialysis with baseline sP data were included in the analysis (KALM-1 and KALM-2, n=845; Study 3105, n=220). Assessments included correlation between 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS) score and sP. Results: In KALM-1 and KALM-2, baseline characteristics in the overall population were similar between patients with sP ≤5.5 and >5.5 mg/dl; no significant correlation was observed between WI-NRS and sP at baseline or in week 12. In patients receiving placebo, no correlation was observed between WI-NRS and sP at baseline or between their change from baseline to week 12 (all P < 0.05). Clinically meaningful (≥3-point) reductions from baseline to week 12 in WI-NRS scores were reported by more patients receiving placebo with baseline sP ≤5.5 mg/dl than >5.5 mg/dl (least squares mean 37.2% versus 27.4%; odds ratio [95% confidence interval], 0.63 [0.41 to 0.97]; P = 0.04). A greater proportion of patients treated with difelikefalin achieved a ≥3-point WI-NRS reduction from baseline to week 12 versus placebo and was similar between sP ≤5.5 and >5.5 mg/dl subgroups (least squares means 51.1% versus 57.6% [P = 0.20]). No significant relationships between sP and WI-NRS in patients receiving difelikefalin were identified in Study 3105 at any time point. Conclusions: No correlation was observed between pruritus severity and sP or response to placebo or difelikefalin in patients with CKD-aP undergoing hemodialysis. Difelikefalin improved itch versus placebo irrespective of baseline sP.
- Open Access
- 28 May 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (7) , 974-986
Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort
Key Points: Hyperkalemia (HK) is associated with increased comorbidity burden in patients with CKD. Reducing serum potassium levels after HK episodes helps continuation of renin-angiotensin-aldosterone system inhibitor treatment. In Japan, HK treatment pathways are more heterogeneous and potassium binders are more commonly prescribed compared with the United Kingdom. Background: This analysis used retrospective data from the DISCOVER CKD observational study (NCT04034992) to describe the burden of and treatment pathways for hyperkalemia (HK) in patients with CKD. Methods: Data were extracted from the following databases: UK Clinical Practice Research Datalink (2008–2019) and Japan Medical Data Vision (2008–2017). Patients with CKD (two eGFR measures 5.0 mmol/L) were compared with patients without HK (sK+ + measurement. Outcomes included baseline characteristics and treatment pathways for key medications (renin-angiotensin-aldosterone system inhibitors [RAASi], diuretics and potassium [K+] binders). Results: In the UK Clinical Practice Research Datalink, 37,713 patients with HK and 142,703 patients without HK were included for analysis (HK prevalence 20.9%). In the Japan Medical Data Vision, 5924 patients with HK and 74,272 patients without HK were included for analysis (HK prevalence 7.4%). In both databases, median eGFR was lower and comorbidities such as hypertension, heart failure, type 2 diabetes, and AKI were more prevalent among patients with versus without HK, and most patients were taking RAASi at the time of HK index. Treatment pathways were more heterogeneous in Japan; + binders within 3 months of HK index versus 18.7% in Japan. The proportions of patients with CKD and HK who stopped treatment with diuretics, K+ binders, and RAASi during follow-up were 48.7%, 76.5%, and 50.6%, respectively, in the United Kingdom, and 22.9%, 53.6%, and 29.2%, respectively, in Japan. Conclusions: HK was associated with increased comorbidity burden in patients with CKD. Variations in treatment pathways between the United Kingdom and Japan reflect the previous lack of a standardized approach to HK management in CKD.
- 28 May 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (7) , 974-986
Open AccessHyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort
Key Points: Hyperkalemia (HK) is associated with increased comorbidity burden in patients with CKD. Reducing serum potassium levels after HK episodes helps continuation of renin-angiotensin-aldosterone system inhibitor treatment. In Japan, HK treatment pathways are more heterogeneous and potassium binders are more commonly prescribed compared with the United Kingdom. Background: This analysis used retrospective data from the DISCOVER CKD observational study (NCT04034992) to describe the burden of and treatment pathways for hyperkalemia (HK) in patients with CKD. Methods: Data were extracted from the following databases: UK Clinical Practice Research Datalink (2008–2019) and Japan Medical Data Vision (2008–2017). Patients with CKD (two eGFR measures 5.0 mmol/L) were compared with patients without HK (sK+ + measurement. Outcomes included baseline characteristics and treatment pathways for key medications (renin-angiotensin-aldosterone system inhibitors [RAASi], diuretics and potassium [K+] binders). Results: In the UK Clinical Practice Research Datalink, 37,713 patients with HK and 142,703 patients without HK were included for analysis (HK prevalence 20.9%). In the Japan Medical Data Vision, 5924 patients with HK and 74,272 patients without HK were included for analysis (HK prevalence 7.4%). In both databases, median eGFR was lower and comorbidities such as hypertension, heart failure, type 2 diabetes, and AKI were more prevalent among patients with versus without HK, and most patients were taking RAASi at the time of HK index. Treatment pathways were more heterogeneous in Japan; + binders within 3 months of HK index versus 18.7% in Japan. The proportions of patients with CKD and HK who stopped treatment with diuretics, K+ binders, and RAASi during follow-up were 48.7%, 76.5%, and 50.6%, respectively, in the United Kingdom, and 22.9%, 53.6%, and 29.2%, respectively, in Japan. Conclusions: HK was associated with increased comorbidity burden in patients with CKD. Variations in treatment pathways between the United Kingdom and Japan reflect the previous lack of a standardized approach to HK management in CKD.
- Open Access
- 12 April 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (6) , 1561-1564
Hypoxia-Inducible Factor Stabilizers: an Evolving Role in Post-Transplant Anemia
- 12 April 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (6) , 1561-1564
Open AccessHypoxia-Inducible Factor Stabilizers: an Evolving Role in Post-Transplant Anemia
- Open Access
- 7 February 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (5) , 732-742
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study
Key Points: Tenapanor, a first-in-class local inhibitor of sodium/hydrogen exchanger isoform 3, acts as a phosphate absorption inhibitor by decreasing paracellular phosphate absorption. Tenapanor alone or with phosphate binders achieved P ≤ 5.5 mg/dl over 10 weeks in 34%–38% of patients taking phosphate binders at baseline. Tenapanor can help adults with CKD on maintenance dialysis achieve normal serum phosphate concentrations. Background: OPTIMIZE was a randomized, open-label study evaluating different tenapanor initiation methods. OPTIMIZE evaluated tenapanor alone and in combination with phosphate binders (PBs) to achieve target serum phosphate (P) ≤5.5 mg/dl. Methods: Patients with inadequately controlled P receiving maintenance dialysis from 42 US locations who were taking PBs with baseline P > 5.5 mg/dl and ≤ 10.0 mg/dl, or were PB-naive with baseline P > 4.5 mg/dl and ≤ 10.0 mg/dl, were included in OPTIMIZE. Participants taking PBs at baseline were randomized to switch from PBs to tenapanor (Straight Switch; n=151) or reduce PB dosage by ≥50% and add tenapanor (Binder Reduction; n=152); PB-naive patients started tenapanor alone (Binder-Naive; n=30). Participants received tenapanor 30 mg twice a day for 10 weeks (part A), followed by an elective, 16-week open-label extension (part B). Outcomes included changes from baseline in P, intact fibroblast growth factor 23, parathyroid hormone, serum calcium, and medication burden; patient-reported outcomes; and safety. Results: By part A end point, 34.4% (Straight Switch), 38.2% (Binder Reduction), and 63.3% (Binder-Naive) of patients achieved P ≤ 5.5 mg/dl. Mean P reduction and median pill burden reduction from baseline to part A end point were 0.91±1.7 mg/dl and 4 pills/d for the Straight Switch and 0.99±1.8 mg/dl and 1 pill/d for the Binder Reduction group. The mean P reduction for Binder-Naive patients was 0.87±1.5 mg/dl. Among Straight Switch and Binder Reduction patients who completed patient experience questionnaires, 205 of 243 (84.4%) reported an improved phosphate management routine. Diarrhea was the most common adverse event (133 of 333 [39.9%]). Conclusions: Tenapanor as monotherapy or in combination with PBs effectively lowered P toward the target range in patients who were PB-naive or who were not at goal despite PB use. Clinical Trial registration number: NCT04549597.
- 7 February 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (5) , 732-742
Open AccessTenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study
Key Points: Tenapanor, a first-in-class local inhibitor of sodium/hydrogen exchanger isoform 3, acts as a phosphate absorption inhibitor by decreasing paracellular phosphate absorption. Tenapanor alone or with phosphate binders achieved P ≤ 5.5 mg/dl over 10 weeks in 34%–38% of patients taking phosphate binders at baseline. Tenapanor can help adults with CKD on maintenance dialysis achieve normal serum phosphate concentrations. Background: OPTIMIZE was a randomized, open-label study evaluating different tenapanor initiation methods. OPTIMIZE evaluated tenapanor alone and in combination with phosphate binders (PBs) to achieve target serum phosphate (P) ≤5.5 mg/dl. Methods: Patients with inadequately controlled P receiving maintenance dialysis from 42 US locations who were taking PBs with baseline P > 5.5 mg/dl and ≤ 10.0 mg/dl, or were PB-naive with baseline P > 4.5 mg/dl and ≤ 10.0 mg/dl, were included in OPTIMIZE. Participants taking PBs at baseline were randomized to switch from PBs to tenapanor (Straight Switch; n=151) or reduce PB dosage by ≥50% and add tenapanor (Binder Reduction; n=152); PB-naive patients started tenapanor alone (Binder-Naive; n=30). Participants received tenapanor 30 mg twice a day for 10 weeks (part A), followed by an elective, 16-week open-label extension (part B). Outcomes included changes from baseline in P, intact fibroblast growth factor 23, parathyroid hormone, serum calcium, and medication burden; patient-reported outcomes; and safety. Results: By part A end point, 34.4% (Straight Switch), 38.2% (Binder Reduction), and 63.3% (Binder-Naive) of patients achieved P ≤ 5.5 mg/dl. Mean P reduction and median pill burden reduction from baseline to part A end point were 0.91±1.7 mg/dl and 4 pills/d for the Straight Switch and 0.99±1.8 mg/dl and 1 pill/d for the Binder Reduction group. The mean P reduction for Binder-Naive patients was 0.87±1.5 mg/dl. Among Straight Switch and Binder Reduction patients who completed patient experience questionnaires, 205 of 243 (84.4%) reported an improved phosphate management routine. Diarrhea was the most common adverse event (133 of 333 [39.9%]). Conclusions: Tenapanor as monotherapy or in combination with PBs effectively lowered P toward the target range in patients who were PB-naive or who were not at goal despite PB use. Clinical Trial registration number: NCT04549597.